Perceptive Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Perceptive Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-30,000	Closed	-$960K	–	106
2018 Q4	$960K	Buy	+30,000	New	+$1.22M	0.04%	82
2018 Q3	–	Sell	-8,085	Closed	-$428K	–	119
2018 Q2	$428K	Hold	8,085	–	–	0.01%	111
2018 Q1	$469K	Buy	+8,085	New	+$503K	0.01%	124
2016 Q2	–	Sell	-2,000	Closed	-$103K	–	174
2016 Q1	$103K	Buy	+2,000	New	+$112K	0.01%	159

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors's ADVM Position: Q1 2019 in Review

Perceptive Advisors sold out of Adverum Biotechnologies (ADVM) in Q1 2019, closing a stake of 30,000 shares — an estimated $960K sold.

Perceptive Advisors first reported a position in ADVM in Q1 2016 and held it in 4 quarters. The position peaked at $960K in Q4 2018. 83 funds tracked by Wall St. Rank hold ADVM as of Q1 2019.

Perceptive Advisors reported no remaining Adverum Biotechnologies position as of Q1 2019 after selling out during the quarter.
Perceptive Advisors sold 30,000 Adverum Biotechnologies shares in Q1 2019, an estimated $960K.
Perceptive Advisors first reported a position in Adverum Biotechnologies in Q1 2016 and held it in 4 quarters.
Perceptive Advisors's Adverum Biotechnologies position peaked at $960K in Q4 2018.
83 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2019.

Based on Perceptive Advisors's 13F filing for Q1 2019, filed 15 May 2019.